Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koo, Tai Yeon | - |
dc.contributor.author | Lee, Ju Han | - |
dc.contributor.author | Min, Sang-Il | - |
dc.contributor.author | Lee, Yonggu | - |
dc.contributor.author | Kim, Myung Soo | - |
dc.contributor.author | Ha, Jongwon | - |
dc.contributor.author | Kim, Soon Il | - |
dc.contributor.author | Ahn, Curie | - |
dc.contributor.author | Kim, Yu Seun | - |
dc.contributor.author | Kim, Jayoun | - |
dc.contributor.author | Huh, Kyu Ha | - |
dc.contributor.author | Yang, Jaeseok | - |
dc.date.accessioned | 2021-07-30T04:42:59Z | - |
dc.date.available | 2021-07-30T04:42:59Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 0085-2538 | - |
dc.identifier.issn | 1523-1755 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/986 | - |
dc.description.abstract | HLA-incompatible living donor kidney transplantation (LDKT) is one of efforts to increase kidney transplantation opportunity for sensitized patients with kidney failure. However, there are conflicting reports for outcomes of HLA-incompatible kidney transplantation compared to patients who wait for HLA-compatible deceased donor kidney transplantation (DDKT) in the United States and United Kingdom. Waiting for an HLA-compatible DDKT is relatively disadvantageous in Korea, because the average waiting time is more than five years. To study this further, we compared outcomes of HLA-incompatible LDKT with those who wait for HLA-compatible DDKT in Korea. One hundred eighty nine patients underwent HLA-incompatible LDKT after desensitization between 2006 and 2018 in two Korean hospitals (42 with a positive complement-dependent cytotoxicity cross-match, 89 with a positive flow cytometric cross-match, and 58 with a positive donor-specific antibody with negative cross-match). The distribution of matched variables was comparable between the HLA-incompatible LDKT group and the matched control groups (waiting-list-only group; and the waiting-list-or-HLA-compatible-DDKT groups; 930 patients each). The HLA-incompatible LDKT group showed a significantly better patient survival rate compared to the waiting-list-only group and the waiting-list-or-HLA-compatible-DDKT groups. Furthermore, the HLA-incompatible LDKT group showed a significant survival benefit as compared with the matched groups at all strength of donor-specific antibodies. Thus, HLA-incompatible LDKT could have a survival benefit as compared with patients who were waitlisted for HLA-compatible DDKT or received HLA-compatible DDKT in Korea. This suggests that HLA-incompatible LDKT as a good option for sensitized patients with kidney failure in countries with prolonged waiting times for DDKT. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.kint.2021.01.027 | - |
dc.identifier.scopusid | 2-s2.0-85103968273 | - |
dc.identifier.wosid | 000667738200027 | - |
dc.identifier.bibliographicCitation | Kidney International, v.100, no.1, pp 206 - 214 | - |
dc.citation.title | Kidney International | - |
dc.citation.volume | 100 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 206 | - |
dc.citation.endPage | 214 | - |
dc.type.docType | Article in Press | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | ANTIBODY-MEDIATED REJECTION | - |
dc.subject.keywordPlus | CROSS-MATCH | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | RECIPIENTS | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | DESENSITIZATION | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | desensitization | - |
dc.subject.keywordAuthor | donor-specific antibody | - |
dc.subject.keywordAuthor | HLA incompatible | - |
dc.subject.keywordAuthor | kidney transplantation | - |
dc.subject.keywordAuthor | waiting time | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0085253821002581?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.